Sezary Syndrome (DBCOND0001518)

Identifiers

Synonyms

Sézary's Disease / Sézary Syndrome / Sézary / Sezany syndrome / Sézary disease / Sezary syndrome / Sezary disease, unspecified site / Sezary disease / Sezary's disease (morphologic abnormality) / Sézary's disease (disorder) / Sezary's syndrome / Sezary's disease / Primary cutaneous T-cell lymphoma (morphologic abnormality) / Cutaneous T-cell lymphoma (morphologic abnormality) / Cutaneous T-cell lymphoma / Primary cutaneous T-cell lymphoma (disorder) / Lymphoma, T-Cell, Cutaneous

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Doxorubicin	A medication used to treat various cancers, including AIDS-associated Kaposi's Sarcoma and metastatic cancers.	DNA topoisomerase 2-alphatarget DNAtarget Cytochrome P450 3A4enzyme Cytochrome P450 2D6enzyme Cytochrome P450 2B6enzyme ATP-dependent translocase ABCB1transporter ATP-binding cassette sub-family C member 3transporter ATP-binding cassette sub-family C member 6transporter Multidrug resistance-associated protein 1transporter ATP-binding cassette sub-family C member 10transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Bile salt export pumptransporter Solute carrier family 22 member 16transporter Mitochondrial potassium channel ATP-binding subunittransporter Cytochrome P450 1B1enzyme Carbonyl reductase [NADPH] 1enzyme Carbonyl reductase [NADPH] 3enzyme Aldo-keto reductase family 1 member A1enzyme Aldo-keto reductase family 1 member C3enzyme NAD(P)H dehydrogenase [quinone] 1enzyme Xanthine dehydrogenase/oxidaseenzyme Nitric oxide synthase 3enzyme Nitric oxide synthase, inducibleenzyme Nitric oxide synthase 1enzyme NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrialenzyme NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrialenzyme NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrialenzyme NADPH--cytochrome P450 reductaseenzyme RalA-binding protein 1transporter ATP-binding cassette sub-family C member 2transporter Albumincarrier Nucleolar and coiled-body phosphoprotein 1target DNA topoisomerase 1target DNA topoisomerase 2-betatarget Aldo-keto reductase family 1 member B1enzyme Aldo-keto reductase family 1 member B10enzyme Aldo-keto reductase family 1 member C4enzyme Telomerase reverse transcriptasetarget
Isotretinoin	A retinoid used to treat severe recalcitrant acne.	Retinoic acid receptor alphatarget Albumincarrier Retinoic acid receptor gammatarget Cytochrome P450 3A4enzyme
Pentostatin	An adenosine deaminase inhibitor used to treat hairy cell leukemia.	Adenosine deaminasetarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04234048	Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma	Fenretinide	treatment	1	recruiting
NCT04676087	Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides	Mogamulizumab	treatment	1 / 2	terminated
NCT04930653	Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma	Mogamulizumab	treatment	2	recruiting
NCT05206045	Evolution of the SURvival of Patients With SEzary Syndrome (SS) Over the 1998-2020 Period and Its Association With the Early Use of Therapeutic Monoclonal Antibodies	No drug interventions	Not Available	Not Available	unknown_status
NCT03373305	Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas	Brentuximab vedotin Lenalidomide	treatment	1	withdrawn
NCT00099593	Immunization Against Tumor Cells in Sezary Syndrome	No drug interventions	treatment	2	completed
NCT03695471	Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides	Pembrolizumab	treatment	2	active_not_recruiting
NCT00254332	Effect of Denileukin Diftitox on Immune System in CTCL Patients	No drug interventions	Not Available	Not Available	completed
NCT00748319	Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma	No drug interventions	diagnostic	Not Available	completed
NCT01134341	Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma	Bexarotene Pralatrexate	treatment	1	completed
NCT04541017	Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment	Magrolimab Mogamulizumab	treatment	1 / 2	active_not_recruiting
NCT03646422	AEDV Registry of Primary Cutaneous Lymphoma	No drug interventions	Not Available	Not Available	recruiting
NCT00157274	Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome	Alemtuzumab	treatment	2	unknown_status
NCT04185220	Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome	Interleukin-15, human recombinant Mogamulizumab	treatment	1	completed
NCT05377827	Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies	WU-CART-007	treatment	1	recruiting
NCT04955340	A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat	Resminostat	treatment	1	completed
NCT00177268	Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research	No drug interventions	Not Available	Not Available	recruiting
NCT03011814	Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma	Durvalumab Lenalidomide	treatment	1 / 2	active_not_recruiting
NCT00611208	A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)	A-dmDT390-bisFv(UCHT1)	treatment	2	completed
NCT00177190	In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)	No drug interventions	Not Available	Not Available	completed
NCT00896493	Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma	Cyclosporine	treatment	2	completed
NCT02341209	Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma	Doxycycline	treatment	2	terminated
NCT02652715	Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma	No drug interventions	basic_science	Not Available	completed
NCT00091559	Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)	Vorinostat	treatment	2	completed
NCT01396070	Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level	Brentuximab vedotin	treatment	2	completed
NCT00050999	Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients	Denileukin diftitox	treatment	4	completed
NCT04960618	Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome	Gemcitabine Pembrolizumab	treatment	2	recruiting
NCT04256018	Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome	Mogamulizumab	treatment	2	recruiting
NCT04312841	Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab	Letermovir	treatment	2	active_not_recruiting
NCT00178841	Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL	Bexarotene Rosiglitazone	treatment	2	completed
NCT05978141	A Registry for People With T-cell Lymphoma	No drug interventions	Not Available	Not Available	recruiting
NCT05879458	Ritlecitinib in CTCL	Ritlecitinib	treatment	2	recruiting
NCT03905135	Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies	Avelumab Interleukin-15, human recombinant	treatment	1	completed
NCT02978625	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	Nivolumab Talimogene laherparepvec	treatment	2	active_not_recruiting
NCT03602157	Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL	Bendamustine Fludarabine	treatment	1	recruiting
NCT00047060	Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome	Alemtuzumab Cyclosporine Fludarabine	treatment	1 / 2	completed
NCT05944562	Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome	No drug interventions	treatment	1	recruiting
NCT03587844	Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients	Brentuximab vedotin	treatment	2	recruiting
NCT02953301	Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)	Resminostat	treatment	2	completed
NCT04904146	Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.	No drug interventions	Not Available	Not Available	recruiting
NCT00051012	Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients	Denileukin diftitox	treatment	4	completed
NCT00127881	Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome	Zanolimumab	treatment	3	terminated
NCT05157581	Extracorporeal Photopheresis in Sezary Syndrome	Methoxsalen	Not Available	Not Available	recruiting
NCT01625455	Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome	Aprepitant	treatment	4	terminated
NCT02811783	Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL	Naloxone	treatment	3	terminated
NCT02542124	NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)	Interleukin-12 human recombinant	treatment	2	unknown_status
NCT02836886	VircapSeq Virus Detection in Sézary Syndrome	No drug interventions	Not Available	Not Available	completed
NCT02840747	Tissue Repository: CTCL Collection Protocol	No drug interventions	Not Available	Not Available	recruiting
NCT02822586	TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome	Brentuximab vedotin	treatment	1	completed